SyntekaBio, Inc.
Research SyntekaBio, Inc. (226330.KQ) on Bullrun: market cap KRW 26.44B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker226330.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyKRW
- Market capKRW 26.44B
- Financial periodQ2 2026
- RevenueKRW 449.25M
- Net income-KRW 2.15B
- Free cash flow-KRW 2.88B
- Gross margin100.0%
Valuation Snapshot
latest market cap is KRW 26.44B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 26.44B | n/a | n/a | n/a |
Dividend history
About SyntekaBio, Inc.
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SyntekaBio, Inc.'s market cap?
SyntekaBio, Inc.'s market capitalization is KRW 26.44B.
What does SyntekaBio, Inc. do?
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology.